Clinical trial NCT05458739: The ClearCoast™ Magnetic Resonance Outcome PMS Study
Official title: The ClearCoast™ Magnetic Resonance Outcome Post Marketing Surveillance Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Lead sponsor: Clear Cut Medical Ltd.
Sponsor class: INDUSTRY
First posted: 2022-07-14
Enrollment: 93
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study population will consist of women 18 years of age and/or over, who are diagnosed with invasive and/or in situ carcinoma of the breast.

Brief summary: Post Marketing Surveillance (PMS) study. Up to 93 patients undergoing breast conserving surgery will be enrolled in a prospective, single center, non-randomized controlled study, and a corresponding number of historical patients that underwent BCS will serve as the historical control group, accounting for a 1:1 ratio. All study patients and the patients in the historical control group will be required to meet the study eligibility criteria.

BCS will be performed with the routine standard of care (SOC), including intra-operative methods used to improve margin assessment. In addition to SOC process, the main specimen from patients found eligible will be scanned in the ClearCoast™ system. The surgeon will utilize the information from the ClearCoast images in his margin assessments evaluation which includes the diffusion at the surface of a particular aspect (suggesting irregular tissue at the specimen's surface), and decide whether to excise additional tissue. The decision-making process including MR images interpretation and the surgical decisions will be evaluated and documented. Following procedure, routine histopathology examination will be performed accompanied by the ClearCoast optical and parametric maps.

This study is a controlled design, in which subjects previously having undergone BCS by the same surgeons, will serve as the historical control group, comparing the following endpoints:

* Complete surgical re-excision rate
* Total excised breast tissue volume

The study Control group is composed of historical data from patients previously undergone BCS, under the same site SOC surgical practice, practicing surgeons, and study eligible criteria. This allows reducing inter-group variability and bias.

A device operator trained by ClearCut Medical will operate the device throughout the study.


Eligibility criteria: Inclusion Criteria:

1. Women histologically diagnosed with invasive and/or in situ carcinoma of the breast, undergoing primary lumpectomy (partial mastectomy) procedure
2. Age ≥18
3. Patient is willing and capable to provide written Informed Consent Form (ICF)

   Exclusion Criteria:
4. Prior surgical procedure in the same breast within 12 months prior to the surgery date
5. Recurrent breast cancer surgery
6. Neoadjuvant chemotherapy and/or neoadjuvant hormone therapy
7. Previous radiation therapy in the operated breast
8. Pregnancy
9. Lactation
10. Patient has subglandular breast implants in the operated breast
11. moribund patient and/or patient with comorbidities, per principal investigator discretion
12. Participating in any other investigational study for either drug or device which might influence collection of valid data under this study.

    Intraoperative:
13. Specimen undergoing pathological specimen assessment (e.g. by frozen section, imprint cytology or gross assessment by sectioning), resulting in deformation of specimen shape/tissue properties (e.g. Formalin conservation)
14. Specimen dimension is larger than the Tissue container volume (200cc)
15. Inability to define aspect color/orientation and/or margin border

Primary outcomes:
measure: ClearCoast™ Success rate
timeFrame: 6 months
Secondary outcomes:
measure: Secondary Outcome - Re-excision rate
timeFrame: 1 year
Other outcomes:
Locations:
city: Frankfurt
country: Germany
facility: Agaplesion Markus Krankenhaus
city: Edinburgh
country: United Kingdom
facility: Western General Hospital , Breast Unit
state: Scotland
Study officials:
References: